This page has only limited features, please log in for full access.

Dr. Murtaza Tambuwala
Ulster University

Basic Info


Research Keywords & Expertise

0 Cancer
0 Histology
0 Inflammation
0 bioprinting
0 inflamatory bowel disease

Fingerprints

Cancer
Inflammation
Histology
bioprinting

Honors and Awards

The user has no records in this section


Career Timeline

The user has no records in this section.


Short Biography

r Murtaza Tambuwala is a Pharmaceutical and Molecular scientist, with an undergraduate degree in Pharmacy and has completed a Masters’ in Pharmaceutical Technology from the School of Pharmacy, Trinity College Dublin. Dr Tambuwala completed his doctoral research focused on elucidating the Hypoxia Inducible Factor (HIF) pathway in intestinal inflammation and the development of colon targeted drug-delivery system to deliver prolyl hydroxylases inhibitors to modulate (HIF) pathway as therapeutic strategy for Inflammatory bowel diseases, at the School of Medicine and Medical Sciences, University College Dublin (2011) under the tutelage of Prof. Cormac Taylor and Dr. Ivan Coulter (CEO of Sublimity Therapeutics); funded by Enterprise Partnership Doctoral Research Award from Irish Research Council. He has also undertaken postdoctoral research training at Trinity Translational Medicine Institute, Trinity College Dublin under the tutelage of Prof. Padraic Fallon funded by a post-doctoral research award obtained from the Irish Research Council. Dr Tambuwala joined Ulster University as a Lecturer in 2013 to establish his independent research in the field of Advanced Drug-delivery to modulate molecular targets using novel and/or repurposed therapeutic agents to combat inflammation, cancer and infection. Dr Tambuwala has published 125 peer-reviewed manuscripts and has co-authored 14 book chapters of books related to drug delivery and molecular medicine.

Following
Followers
Co Authors
The list of users this user is following is empty.
Following: 0 users

Feed

Review
Published: 18 August 2021 in Bioengineering & Translational Medicine
Reads 0
Downloads 0

More than five decades have been invested in understanding glucose biosensors. Yet, this immensely versatile field has continued to gain attention from the scientific world to better understand and diagnose diabetes. However, such extensive work done to improve glucose sensing devices has still not yielded desirable results. Drawbacks like the necessity of the invasive finger pricking step and the lack of optimization of diagnostic interventions still need to be considered to improve the testing process of diabetic patients. To upgrade the glucose-sensing devices and reduce the number of intermediary steps during glucose measurement, fourth-generation glucose sensors (FGGS) have been introduced. These sensors, made using robust electrocatalytic copper nanostructures, improve diagnostic efficiency and cost-effectiveness. This review aims to present the essential scientific progress in copper nanostructure-based FGGS in the past ten years (2010 – present). After a short introduction, we presented the working principles of these sensors. We then highlighted the importance of copper nanostructures as advanced electrode materials to develop reliable real-time FGGS. Finally, we cover the advantages, shortcomings, and prospects for developing highly sensitive, stable, and specific FGGS.

ACS Style

Tasbiha Awan; Gowhar A. Naikoo; Hiba Salim; Fareeha Arshad; Israr U. Hassan; Mona Zamani Pedram; Waqar Ahmed; Hakkim L. Faruck; Alaa A. A. Aljabali; Vijay Mishra; Ángel Serrano‐Aroca; Rohit Goyal; Poonam Negi; Martin Birkett; Mohamed M. Nasef; Nitin B. Charbe; Hamid A. Bakshi; Murtaza M. Tambuwala. Fourth Generation Glucose Sensors Composed of Copper Nanostructures for Diabetes Management: A Critical Review. Bioengineering & Translational Medicine 2021, e10248 .

AMA Style

Tasbiha Awan, Gowhar A. Naikoo, Hiba Salim, Fareeha Arshad, Israr U. Hassan, Mona Zamani Pedram, Waqar Ahmed, Hakkim L. Faruck, Alaa A. A. Aljabali, Vijay Mishra, Ángel Serrano‐Aroca, Rohit Goyal, Poonam Negi, Martin Birkett, Mohamed M. Nasef, Nitin B. Charbe, Hamid A. Bakshi, Murtaza M. Tambuwala. Fourth Generation Glucose Sensors Composed of Copper Nanostructures for Diabetes Management: A Critical Review. Bioengineering & Translational Medicine. 2021; ():e10248.

Chicago/Turabian Style

Tasbiha Awan; Gowhar A. Naikoo; Hiba Salim; Fareeha Arshad; Israr U. Hassan; Mona Zamani Pedram; Waqar Ahmed; Hakkim L. Faruck; Alaa A. A. Aljabali; Vijay Mishra; Ángel Serrano‐Aroca; Rohit Goyal; Poonam Negi; Martin Birkett; Mohamed M. Nasef; Nitin B. Charbe; Hamid A. Bakshi; Murtaza M. Tambuwala. 2021. "Fourth Generation Glucose Sensors Composed of Copper Nanostructures for Diabetes Management: A Critical Review." Bioengineering & Translational Medicine , no. : e10248.

Journal article
Published: 16 August 2021 in Current Molecular Pharmacology
Reads 0
Downloads 0

Hypoxia is an integral part of the tumor microenvironment, caused primarily due to rapidly multiplying tumor cells and a lack of proper blood supply. Among the major hypoxic pathways, HIF-1 transcription factor activation is one of the widely investigated pathways in the hypoxic tumor microenvironment (TME). HIF-1 is known to activate several adaptive reactions in response to oxygen deficiency in tumor cells. HIF-1 has two subunits, HIF-1β (constitutive) and HIF-1α (inducible). The HIF-1α expression is largely regulated via various cytokines (through PI3K-ACT-mTOR signals), which involves the cascading of several growth factors and oncogenic cascades. These events lead to the loss of cellular tumor suppressant activity through changes in the level of oxygen via oxygen-dependent and oxygen-independent pathways. The significant and crucial role of HIF in cancer progression and its underlying mechanisms have gained much attention lately among the translational researchers in the fields of cancer and biological sciences, which have enabled them to correlate these mechanisms with various other disease modalities. In the present review, we have summarized the key findings related to the role of HIF in the progression of tumors.

ACS Style

Saurabh Satija; Harpreet Kaur; Murtaza M. Tambuwala; Prabal Sharma; Manish Vyas; Navneet Khurana; Neha Sharma; Hamid A. Bakshi; Nitin B. Charbe; Flavia C. Zacconi; Alaa A. Aljabali; Srinivas Nammi; Harish Dureja; Thakur G. Singh; Gaurav Gupta; Daljeet S. Dhanjal; Kamal Dua; Dinesh K. Chellappan; Meenu Mehta. Hypoxia-Inducible Factor (HIF): Fuel for Cancer Progression. Current Molecular Pharmacology 2021, 14, 321 -332.

AMA Style

Saurabh Satija, Harpreet Kaur, Murtaza M. Tambuwala, Prabal Sharma, Manish Vyas, Navneet Khurana, Neha Sharma, Hamid A. Bakshi, Nitin B. Charbe, Flavia C. Zacconi, Alaa A. Aljabali, Srinivas Nammi, Harish Dureja, Thakur G. Singh, Gaurav Gupta, Daljeet S. Dhanjal, Kamal Dua, Dinesh K. Chellappan, Meenu Mehta. Hypoxia-Inducible Factor (HIF): Fuel for Cancer Progression. Current Molecular Pharmacology. 2021; 14 (3):321-332.

Chicago/Turabian Style

Saurabh Satija; Harpreet Kaur; Murtaza M. Tambuwala; Prabal Sharma; Manish Vyas; Navneet Khurana; Neha Sharma; Hamid A. Bakshi; Nitin B. Charbe; Flavia C. Zacconi; Alaa A. Aljabali; Srinivas Nammi; Harish Dureja; Thakur G. Singh; Gaurav Gupta; Daljeet S. Dhanjal; Kamal Dua; Dinesh K. Chellappan; Meenu Mehta. 2021. "Hypoxia-Inducible Factor (HIF): Fuel for Cancer Progression." Current Molecular Pharmacology 14, no. 3: 321-332.

Review
Published: 31 July 2021 in Applied Sciences
Reads 0
Downloads 0

Fungal infections, from mild itching to fatal infections, lead to chronic diseases and death. Antifungal agents have incorporated chemical compounds and natural products/phytoconstituents in the management of fungal diseases. In contrast to antibacterial research, novel antifungal drugs have progressed more swiftly because of their mild existence and negligible resistance of infections to antifungal bioactivities. Nanotechnology-based carriers have gained much attention due to their magnificent abilities. Nanoarchitectures have served as excellent carriers/drug delivery systems (DDS) for delivering antifungal drugs with improved antifungal activities, bioavailability, targeted action, and reduced cytotoxicity. This review outlines the different fungal diseases and their treatment strategies involving various nanocarrier-based techniques such as liposomes, transfersomes, ethosomes, transethosomes, niosomes, spanlastics, dendrimers, polymeric nanoparticles, polymer nanocomposites, metallic nanoparticles, carbon nanomaterials, and nanoemulsions, among other nanotechnological approaches.

ACS Style

Vijay Mishra; Manvendra Singh; Yachana Mishra; Nitin Charbe; Pallavi Nayak; Kalvatala Sudhakar; Alaa Aljabali; Seyed Shahcheraghi; Hamid Bakshi; Ángel Serrano-Aroca; Murtaza Tambuwala. Nanoarchitectures in Management of Fungal Diseases: An Overview. Applied Sciences 2021, 11, 7119 .

AMA Style

Vijay Mishra, Manvendra Singh, Yachana Mishra, Nitin Charbe, Pallavi Nayak, Kalvatala Sudhakar, Alaa Aljabali, Seyed Shahcheraghi, Hamid Bakshi, Ángel Serrano-Aroca, Murtaza Tambuwala. Nanoarchitectures in Management of Fungal Diseases: An Overview. Applied Sciences. 2021; 11 (15):7119.

Chicago/Turabian Style

Vijay Mishra; Manvendra Singh; Yachana Mishra; Nitin Charbe; Pallavi Nayak; Kalvatala Sudhakar; Alaa Aljabali; Seyed Shahcheraghi; Hamid Bakshi; Ángel Serrano-Aroca; Murtaza Tambuwala. 2021. "Nanoarchitectures in Management of Fungal Diseases: An Overview." Applied Sciences 11, no. 15: 7119.

Preprint
Published: 26 July 2021
Reads 0
Downloads 0

The devastating impact of the ongoing coronavirus disease 2019 (COVID-19) on public health, caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has made fighting of the COVID-19 pandemic is a top priority in medical research and pharmaceutical development. Surveillance of SARS-CoV-2 mutations is essential for the comprehension of SARS-CoV-2 variant diversity and their impact on virulence and pathogenicity. The SARS-CoV-2 open reading frame 10 (ORF10) protein interacts with multiple human proteins CUL2, ELOB, ELOC, MAP7D1, PPT1, RBX1, THTPA, TIMM8B, and ZYG11B expressed in the lung tissues. Mutations and co-mutations in the emerging SARS-CoV-2 ORF10 variants are expected to impact the severity of the virus and its associated consequences. In this article, We highlight 128 single mutations and 35 co-mutations in the unique SARS-CoV-2 ORF10 variants in this article. The possible predicted effects of these mutations and co-mutations on the secondary structure of ORF10 variants and host protein interactomes are presented. The findings highlight the possible effects of mutations and co-mutations on the emerging 140 ORF10 unique variants from secondary structure and intrinsic protein disorder perspectives.

ACS Style

Sk. Sarif Hassan; Kenneth Lundstrom; Ángel Serrano-Aroca; Parise Adadi; Alaa Aljabali; ElRashdy Redwan; Amos Lal; Ramesh Kandimalla; Tarek El-Aziz; Pabitra Choudhury; Gajendra Azad; Samendra Sherchan; Murtaza Tambuwala; Gaurav Chauhan; Kazuo Takayama; Debmalya Barh; Giorgio Palù; Pallab Basu; Vladimir N Uversky. Emergence of Unique SARS-CoV-2 ORF10 Variants and Their Impact on Protein Structure and Function. 2021, 1 .

AMA Style

Sk. Sarif Hassan, Kenneth Lundstrom, Ángel Serrano-Aroca, Parise Adadi, Alaa Aljabali, ElRashdy Redwan, Amos Lal, Ramesh Kandimalla, Tarek El-Aziz, Pabitra Choudhury, Gajendra Azad, Samendra Sherchan, Murtaza Tambuwala, Gaurav Chauhan, Kazuo Takayama, Debmalya Barh, Giorgio Palù, Pallab Basu, Vladimir N Uversky. Emergence of Unique SARS-CoV-2 ORF10 Variants and Their Impact on Protein Structure and Function. . 2021; ():1.

Chicago/Turabian Style

Sk. Sarif Hassan; Kenneth Lundstrom; Ángel Serrano-Aroca; Parise Adadi; Alaa Aljabali; ElRashdy Redwan; Amos Lal; Ramesh Kandimalla; Tarek El-Aziz; Pabitra Choudhury; Gajendra Azad; Samendra Sherchan; Murtaza Tambuwala; Gaurav Chauhan; Kazuo Takayama; Debmalya Barh; Giorgio Palù; Pallab Basu; Vladimir N Uversky. 2021. "Emergence of Unique SARS-CoV-2 ORF10 Variants and Their Impact on Protein Structure and Function." , no. : 1.

Review
Published: 18 July 2021 in Viruses
Reads 0
Downloads 0

The recent coronavirus disease 2019 (COVID-19) outbreak has drawn global attention, affecting millions, disrupting economies and healthcare modalities. With its high infection rate, COVID-19 has caused a colossal health crisis worldwide. While information on the comprehensive nature of this infectious agent, SARS-CoV-2, still remains obscure, ongoing genomic studies have been successful in identifying its genomic sequence and the presenting antigen. These may serve as promising, potential therapeutic targets in the effective management of COVID-19. In an attempt to establish herd immunity, massive efforts have been directed and driven toward developing vaccines against the SARS-CoV-2 pathogen. This review, in this direction, is aimed at providing the current scenario and future perspectives in the development of vaccines against SARS-CoV-2.

ACS Style

Wai Chong; Dinesh Chellappan; Shakti Shukla; Gregory Peterson; Rahul Patel; Niraj Jha; Rajaraman Eri; Kamal Dua; Murtaza Tambuwala; Madhur Shastri. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses 2021, 13, 1397 .

AMA Style

Wai Chong, Dinesh Chellappan, Shakti Shukla, Gregory Peterson, Rahul Patel, Niraj Jha, Rajaraman Eri, Kamal Dua, Murtaza Tambuwala, Madhur Shastri. An Appraisal of the Current Scenario in Vaccine Research for COVID-19. Viruses. 2021; 13 (7):1397.

Chicago/Turabian Style

Wai Chong; Dinesh Chellappan; Shakti Shukla; Gregory Peterson; Rahul Patel; Niraj Jha; Rajaraman Eri; Kamal Dua; Murtaza Tambuwala; Madhur Shastri. 2021. "An Appraisal of the Current Scenario in Vaccine Research for COVID-19." Viruses 13, no. 7: 1397.

Journal article
Published: 15 July 2021 in Future Oncology
Reads 0
Downloads 0

The mortality and morbidity rates for prostate cancer have recently increased to alarming levels, rising higher than lung cancer. Due to a lack of drug targets and molecular probes, existing theranostic techniques are limited. Human LIN28A and its paralog LIN28B overexpression are associated with a number of tumors resulting in a remarkable increase in cancer aggression and poor prognoses. The current review aims to highlight recent work identifying the key roles of LIN28A and LIN28B in prostate cancer, and to instigate further preclinical and clinical research in this important area.

ACS Style

Garima Shrivastava; Alaa Aa Aljabali; Seyed Hossein Shahcheraghi; Marzieh Lotfi; Madhur D Shastri; Shakti D Shukla; Dinesh K Chellappan; Niraj Kumar Jha; Krishnan Anand; Harish Dureja; Ritesh M Pabari; Vijay Mishra; Abdulmajeed G Almutary; Abdullah M Alnuqaydan; Nitin Charbe; Parteek Prasher; Poonam Negi; Rohit Goyal; Kamal Dua; Gaurav Gupta; Ángel Serrano-Aroca; Bojlul Bahar; Debmalya Barh; Pritam Kumar Panda; Kazuo Takayama; Kenneth Lundstorm; Paul McCarron; Hamid Bakshi; Murtaza M Tambuwala. Targeting LIN28: a new hope in prostate cancer theranostics. Future Oncology 2021, 1 .

AMA Style

Garima Shrivastava, Alaa Aa Aljabali, Seyed Hossein Shahcheraghi, Marzieh Lotfi, Madhur D Shastri, Shakti D Shukla, Dinesh K Chellappan, Niraj Kumar Jha, Krishnan Anand, Harish Dureja, Ritesh M Pabari, Vijay Mishra, Abdulmajeed G Almutary, Abdullah M Alnuqaydan, Nitin Charbe, Parteek Prasher, Poonam Negi, Rohit Goyal, Kamal Dua, Gaurav Gupta, Ángel Serrano-Aroca, Bojlul Bahar, Debmalya Barh, Pritam Kumar Panda, Kazuo Takayama, Kenneth Lundstorm, Paul McCarron, Hamid Bakshi, Murtaza M Tambuwala. Targeting LIN28: a new hope in prostate cancer theranostics. Future Oncology. 2021; ():1.

Chicago/Turabian Style

Garima Shrivastava; Alaa Aa Aljabali; Seyed Hossein Shahcheraghi; Marzieh Lotfi; Madhur D Shastri; Shakti D Shukla; Dinesh K Chellappan; Niraj Kumar Jha; Krishnan Anand; Harish Dureja; Ritesh M Pabari; Vijay Mishra; Abdulmajeed G Almutary; Abdullah M Alnuqaydan; Nitin Charbe; Parteek Prasher; Poonam Negi; Rohit Goyal; Kamal Dua; Gaurav Gupta; Ángel Serrano-Aroca; Bojlul Bahar; Debmalya Barh; Pritam Kumar Panda; Kazuo Takayama; Kenneth Lundstorm; Paul McCarron; Hamid Bakshi; Murtaza M Tambuwala. 2021. "Targeting LIN28: a new hope in prostate cancer theranostics." Future Oncology , no. : 1.

Opinion
Published: 13 July 2021 in Biomolecules
Reads 0
Downloads 0

Two adenovirus-based vaccines, ChAdOx1 nCoV-19 and Ad26.COV2.S, and two mRNA-based vaccines, BNT162b2 and mRNA.1273, have been approved by the European Medicines Agency (EMA), and are invaluable in preventing and reducing the incidence of coronavirus disease-2019 (COVID-19). Recent reports have pointed to thrombosis with associated thrombocytopenia as an adverse effect occurring at a low frequency in some individuals after vaccination. The causes of such events may be related to SARS-CoV-2 spike protein interactions with different C-type lectin receptors, heparan sulfate proteoglycans (HSPGs) and the CD147 receptor, or to different soluble splice variants of the spike protein, adenovirus vector interactions with the CD46 receptor or platelet factor 4 antibodies. Similar findings have been reported for several viral diseases after vaccine administration. In addition, immunological mechanisms elicited by viral vectors related to cellular delivery could play a relevant role in individuals with certain genetic backgrounds. Although rare, the potential COVID-19 vaccine-induced immune thrombotic thrombocytopenia (VITT) requires immediate validation, especially in risk groups, such as the elderly, chronic smokers, and individuals with pre-existing incidences of thrombocytopenia; and if necessary, a reformulation of existing vaccines.

ACS Style

Kenneth Lundstrom; Debmalya Barh; Bruce Uhal; Kazuo Takayama; Alaa Aljabali; Tarek Abd El-Aziz; Amos Lal; ElRashdy Redwan; Parise Adadi; Gaurav Chauhan; Samendra Sherchan; Gajendra Azad; Nima Rezaei; Ángel Serrano-Aroca; Nicolas Bazan; Sk Hassan; Pritam Panda; Pabitra Pal Choudhury; Damiano Pizzol; Ramesh Kandimalla; Wagner Baetas-Da-Cruz; Yogendra Mishra; Giorgio Palu; Adam Brufsky; Murtaza Tambuwala; Vladimir Uversky. COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street? Biomolecules 2021, 11, 1020 .

AMA Style

Kenneth Lundstrom, Debmalya Barh, Bruce Uhal, Kazuo Takayama, Alaa Aljabali, Tarek Abd El-Aziz, Amos Lal, ElRashdy Redwan, Parise Adadi, Gaurav Chauhan, Samendra Sherchan, Gajendra Azad, Nima Rezaei, Ángel Serrano-Aroca, Nicolas Bazan, Sk Hassan, Pritam Panda, Pabitra Pal Choudhury, Damiano Pizzol, Ramesh Kandimalla, Wagner Baetas-Da-Cruz, Yogendra Mishra, Giorgio Palu, Adam Brufsky, Murtaza Tambuwala, Vladimir Uversky. COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street? Biomolecules. 2021; 11 (7):1020.

Chicago/Turabian Style

Kenneth Lundstrom; Debmalya Barh; Bruce Uhal; Kazuo Takayama; Alaa Aljabali; Tarek Abd El-Aziz; Amos Lal; ElRashdy Redwan; Parise Adadi; Gaurav Chauhan; Samendra Sherchan; Gajendra Azad; Nima Rezaei; Ángel Serrano-Aroca; Nicolas Bazan; Sk Hassan; Pritam Panda; Pabitra Pal Choudhury; Damiano Pizzol; Ramesh Kandimalla; Wagner Baetas-Da-Cruz; Yogendra Mishra; Giorgio Palu; Adam Brufsky; Murtaza Tambuwala; Vladimir Uversky. 2021. "COVID-19 Vaccines and Thrombosis—Roadblock or Dead-End Street?" Biomolecules 11, no. 7: 1020.

Journal article
Published: 09 July 2021 in Anti-Cancer Agents in Medicinal Chemistry
Reads 0
Downloads 0

Background: Silver nanoparticles (AgNPs) are among the most investigated nanostructures in recent years, which exhibit more challenging and promising qualities in different biomedical applications. The AgNPs synthesized by the green approach provide potential healthcare benefits over chemical approaches, including improvement of tissue restoration, drug delivery, diagnosis, being environmentally friendly, and a boon to cancer treatment. Objective: In the current scenario, the development of safe and effective drug delivery systems is the utmost concern of formulation development scientists as well as clinicians. Methods: Google, Web of Science, and PubMed portals have been searched for potentially relevant literature to get the latest developments and updated information related to different aspects of green synthesized AgNPs along with their biomedical applications, especially in the treatment of different types of cancers. Results: The present review highlights the latest published research regarding the different green approaches for the synthesis of AgNPs, their characterization techniques as well as various biomedical applications, particularly in cancer treatment. In this context, environment-friendly AgNPs are proving themselves as better candidates in terms of size, drug loading and release efficiency, targeting efficiency, minimal drug-associated side effects, pharmacokinetic profiling, and biocompatibility issues. Conclusion: With continuous efforts by multidisciplinary team approaches, nanotechnology-based AgNPs will shed new light on diagnostics and therapeutics in various disease treatments. However, the toxicity issues of AgNPs need greater attention as unanticipated toxic effects must be ruled out for their diversified applications.

ACS Style

Vijay Mishra; Pallavi Nayak; Manvendra Singh; Murtaza M. Tambuwala; Alaa A. Aljabali; Dinesh K. Chellappan; Kamal Dua. Pharmaceutical Aspects of Green Synthesized Silver Nanoparticles: A Boon to Cancer Treatment. Anti-Cancer Agents in Medicinal Chemistry 2021, 21, 1490 -1509.

AMA Style

Vijay Mishra, Pallavi Nayak, Manvendra Singh, Murtaza M. Tambuwala, Alaa A. Aljabali, Dinesh K. Chellappan, Kamal Dua. Pharmaceutical Aspects of Green Synthesized Silver Nanoparticles: A Boon to Cancer Treatment. Anti-Cancer Agents in Medicinal Chemistry. 2021; 21 (12):1490-1509.

Chicago/Turabian Style

Vijay Mishra; Pallavi Nayak; Manvendra Singh; Murtaza M. Tambuwala; Alaa A. Aljabali; Dinesh K. Chellappan; Kamal Dua. 2021. "Pharmaceutical Aspects of Green Synthesized Silver Nanoparticles: A Boon to Cancer Treatment." Anti-Cancer Agents in Medicinal Chemistry 21, no. 12: 1490-1509.

Journal article
Published: 01 July 2021 in Nanomedicine
Reads 0
Downloads 0
ACS Style

Yinghan Chan; Ronan MacLoughlin; Flavia C Zacconi; Murtaza M Tambuwala; Ritesh M Pabari; Sachin Kumar Singh; Terezinha De Jesus Andreoli Pinto; Gaurav Gupta; Dinesh Kumar Chellappan; Kamal Dua. Advances in nanotechnology-based drug delivery in targeting PI3K signaling in respiratory diseases. Nanomedicine 2021, 16, 1351 -1355.

AMA Style

Yinghan Chan, Ronan MacLoughlin, Flavia C Zacconi, Murtaza M Tambuwala, Ritesh M Pabari, Sachin Kumar Singh, Terezinha De Jesus Andreoli Pinto, Gaurav Gupta, Dinesh Kumar Chellappan, Kamal Dua. Advances in nanotechnology-based drug delivery in targeting PI3K signaling in respiratory diseases. Nanomedicine. 2021; 16 (16):1351-1355.

Chicago/Turabian Style

Yinghan Chan; Ronan MacLoughlin; Flavia C Zacconi; Murtaza M Tambuwala; Ritesh M Pabari; Sachin Kumar Singh; Terezinha De Jesus Andreoli Pinto; Gaurav Gupta; Dinesh Kumar Chellappan; Kamal Dua. 2021. "Advances in nanotechnology-based drug delivery in targeting PI3K signaling in respiratory diseases." Nanomedicine 16, no. 16: 1351-1355.

Preprint
Published: 18 June 2021
Reads 0
Downloads 0

Several hypotheses have been presented on the origin of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) from its identification as the agent causing the current coronavirus disease 19 (COVID-19) pandemic. So far, no hypothesis has managed to identify the origin, and the issue has resurfaced. Here we have unfolded a pattern of distribution of several mutations in the SARS-CoV-2 proteins across different continents comprising 24 geo-locations. The results showed an evenly uneven distribution of unique protein variants, distinct mutations, unique frequency of common conserved residues, and mutational residues across the 24 geo-locations. Furthermore, ample mutations were identified in the evolutionarily conserved invariant regions in the SARS-CoV-2 proteins across almost all geo-locations we have considered. This pattern of mutations potentially breaches the law of evolutionary conserved functional units of the beta-coronavirus genus. These mutations may lead to several novel SARS-CoV-2 variants with a high degree of transmissibility and virulence. A thorough investigation on the origin and characteristics of SARS-CoV-2 needs to be conducted in the interest of science and to be prepared to meet the challenges of potential future pandemics.

ACS Style

Sk Sarif Hassan; Vaishnavi Kodakandla; Elrashdy M. Redwan; Kenneth Lundstrom; Pabitra Pal Choudhury; Ángel Serrano-Aroca Aroca; Gajendra Kumar Azad; Alaa A.A. Aljabali; Giorgio Palu; Tarek Mohamed Abd El-Aziz; Debmalya Barh; Bruce D. Uhal; Parise Adadi; Kazuo Takayama; Nicolas G. Bazan; Murtaza Tambuwala; Samendra P. Sherchan; Amos Lal; Gaurav Chauhan; Wagner Baetas-Da-Cruz; Vladimir N. Uversky. Non-Uniform Aspects of SARS-CoV-2 Intraspecies Evolution Reopen Questions on Its Origin. 2021, 1 .

AMA Style

Sk Sarif Hassan, Vaishnavi Kodakandla, Elrashdy M. Redwan, Kenneth Lundstrom, Pabitra Pal Choudhury, Ángel Serrano-Aroca Aroca, Gajendra Kumar Azad, Alaa A.A. Aljabali, Giorgio Palu, Tarek Mohamed Abd El-Aziz, Debmalya Barh, Bruce D. Uhal, Parise Adadi, Kazuo Takayama, Nicolas G. Bazan, Murtaza Tambuwala, Samendra P. Sherchan, Amos Lal, Gaurav Chauhan, Wagner Baetas-Da-Cruz, Vladimir N. Uversky. Non-Uniform Aspects of SARS-CoV-2 Intraspecies Evolution Reopen Questions on Its Origin. . 2021; ():1.

Chicago/Turabian Style

Sk Sarif Hassan; Vaishnavi Kodakandla; Elrashdy M. Redwan; Kenneth Lundstrom; Pabitra Pal Choudhury; Ángel Serrano-Aroca Aroca; Gajendra Kumar Azad; Alaa A.A. Aljabali; Giorgio Palu; Tarek Mohamed Abd El-Aziz; Debmalya Barh; Bruce D. Uhal; Parise Adadi; Kazuo Takayama; Nicolas G. Bazan; Murtaza Tambuwala; Samendra P. Sherchan; Amos Lal; Gaurav Chauhan; Wagner Baetas-Da-Cruz; Vladimir N. Uversky. 2021. "Non-Uniform Aspects of SARS-CoV-2 Intraspecies Evolution Reopen Questions on Its Origin." , no. : 1.

Journal article
Published: 17 June 2021 in Current Pharmaceutical Design
Reads 0
Downloads 0

: Ulcerative colitis (UC) is one of the main subtypes of inflammatory bowel disease. UC has a negative effect on patients’ quality of life, and it is an important risk factor for the development of colitis-associated cancer. Patients with UC need to take medications for their entire life because no permanent cure is available. Therefore, approaches that target messenger RNA (mRNA) of proinflammatory cytokines or anti-inflammatory cytokines are needed to improve the safety of UC therapy and promote intestinal mucosa recovery. The major challenge facing RNA interference-based therapy is the delivery of RNA molecules to the intracellular space of target cells. Moreover, nonspecific and systemic protein expression inhibition can result in adverse effects and less therapeutic benefits. Thus, it is important to develop an efficient delivery strategy targeting the cytoplasm of target cells to avoid side effects caused by off-target protein expression inhibition. This review focuses on the most recent advances in the targeted nano delivery systems of siRNAs and mRNA that have shown in vivo efficacy.

ACS Style

Iman Alfagih; Basmah Aldosari; Bushra AlQuadeib; Alanood Almurshedi; Murtaza Tambuwala. An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis. Current Pharmaceutical Design 2021, 27, 1 -1.

AMA Style

Iman Alfagih, Basmah Aldosari, Bushra AlQuadeib, Alanood Almurshedi, Murtaza Tambuwala. An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis. Current Pharmaceutical Design. 2021; 27 ():1-1.

Chicago/Turabian Style

Iman Alfagih; Basmah Aldosari; Bushra AlQuadeib; Alanood Almurshedi; Murtaza Tambuwala. 2021. "An Overview of nano delivery systems for targeting RNA interference-based therapy in ulcerative colitis." Current Pharmaceutical Design 27, no. : 1-1.

Preprint content
Published: 25 May 2021
Reads 0
Downloads 0

Open reading frame 8 (ORF8) protein is one of the most evolving accessory proteins in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19). It was previously reported that the ORF8 protein inhibits presentation of viral antigens by the major histocompatibility complex class I (MHC-I) and interacts with host factors involved in pulmonary inflammation. The ORF8 protein assists SARS-CoV-2 to evade immunity and replication. Among many contributing mutations, Q27STOP, a mutation in the ORF8 protein defines the B.1.1.7 lineage of SARS-CoV-2, which is engendering the second wave of COVID-19. In the present study, 47 unique truncated ORF8 proteins (T-ORF8) due to the Q27STOP mutations were identified among 49055 available B.1.1.7 SARS-CoV-2 sequences. The results show that only one of the 47 T-ORF8 variants spread to over 57 geo-locations in North America, and other continents which includes Africa, Asia, Europe and South America. Based on various quantitative features such as amino acid homology, polar/non-polar sequence homology, Shannon entropy conservation, and other physicochemical properties of all specific 47 T-ORF8 protein variants, a collection of nine possible T-ORF8 unique variants were defined. The question of whether T-ORF8 variants work similarly to ORF8 has yet to be investigated. A positive response to the question could exacerbate future COVID-19 waves, necessitating severe containment measures.

ACS Style

Sk. Sarif Hassan; Vaishnavi Kodakandla; Elrashdy M. Redwan; Kenneth Lundstrom; Pabitra Pal Choudhury; Tarek Mohamed Abd El-Aziz; Kazuo Takayama; Ramesh Kandimalla; Amos Lal; Ángel Serrano-Aroca; Gajendra Kumar Azad; Alaa A. A. Aljabali; Giorgio Palu; Gaurav Chauhan; Parise Adadi; Murtaza Tambuwala; Adam M. Brufsky; Wagner Baetas-Da-Cruz; Debmalya Barh; Nicolas G Bazan; Vladimir N. Uversky. An Issue of Concern: Unique Truncated ORF8 Protein Variants of SARS-CoV-2. 2021, 1 .

AMA Style

Sk. Sarif Hassan, Vaishnavi Kodakandla, Elrashdy M. Redwan, Kenneth Lundstrom, Pabitra Pal Choudhury, Tarek Mohamed Abd El-Aziz, Kazuo Takayama, Ramesh Kandimalla, Amos Lal, Ángel Serrano-Aroca, Gajendra Kumar Azad, Alaa A. A. Aljabali, Giorgio Palu, Gaurav Chauhan, Parise Adadi, Murtaza Tambuwala, Adam M. Brufsky, Wagner Baetas-Da-Cruz, Debmalya Barh, Nicolas G Bazan, Vladimir N. Uversky. An Issue of Concern: Unique Truncated ORF8 Protein Variants of SARS-CoV-2. . 2021; ():1.

Chicago/Turabian Style

Sk. Sarif Hassan; Vaishnavi Kodakandla; Elrashdy M. Redwan; Kenneth Lundstrom; Pabitra Pal Choudhury; Tarek Mohamed Abd El-Aziz; Kazuo Takayama; Ramesh Kandimalla; Amos Lal; Ángel Serrano-Aroca; Gajendra Kumar Azad; Alaa A. A. Aljabali; Giorgio Palu; Gaurav Chauhan; Parise Adadi; Murtaza Tambuwala; Adam M. Brufsky; Wagner Baetas-Da-Cruz; Debmalya Barh; Nicolas G Bazan; Vladimir N. Uversky. 2021. "An Issue of Concern: Unique Truncated ORF8 Protein Variants of SARS-CoV-2." , no. : 1.

Review
Published: 21 May 2021 in Current Medical Imaging Formerly Current Medical Imaging Reviews
Reads 0
Downloads 0

Background: Nature had already engineered various types of nanoparticles (NPs), especially viruses, which can deliver their cargo to the host/targeted cells. The ability to selectively target specific cells offers a significant advantage over the conventional approach. Numerous organic NPs, including native protein cages, virus-like pieces, polymeric saccharides, and liposomes, have been used for the preparation of nanoparticulate. Such nanomaterials have demonstrated better performance and as well as improved biocompatible, devoid of side effects, and stable without any deterioration. Objective: This review discusses current clinical and scientific research on naturally occurring nanomaterials. The review illustrates and updates the tailor-made approaches for selective delivery and targeted medications that require a highaffinity interconnection to the targeted cells. Method: A comprehensive search was performed using keywords for viral nanoparticles, viral particles for drug delivery, viral nanoparticles for molecular imaging, theranostics applications of viral nanoparticles and plant viruses in nanomedicine. We searched in Google Scholar, PubMed, Springer, Medline, and Elsevier from 2000 to till date and by the bibliographic review of all identified articles. Results: The findings demonstrated that structures dependent on nanomaterials might have potential applications in diagnostics, cell marking, comparing agents (computed tomography and magnetic resonance imaging), and antimicrobial drugs, as well as drug delivery structures. However, measures should be taken in order to prevent or mitigate in pharmaceutical or medical applications the toxic impact or incompatibility of nanoparticle-based structures with biological systems. Conclusion: The review provided an overview of the latest advances in nanotechnology, outlining the difficulties and the advantages of in vivo and in vitro structures that are focused on a specific subset of the natural nanomaterials.

ACS Style

Alaa A.A. Aljabali; Mazhar S. Al Zoubi; Khalid M. Al-Batayneh; Dinesh M. Pardhi; Kamal Dua; Kaushik Pal; Murtaza M. Tambuwala. Innovative Applications of Plant Viruses in Drug Targeting and Molecular Imaging- A Review. Current Medical Imaging Formerly Current Medical Imaging Reviews 2021, 17, 491 -506.

AMA Style

Alaa A.A. Aljabali, Mazhar S. Al Zoubi, Khalid M. Al-Batayneh, Dinesh M. Pardhi, Kamal Dua, Kaushik Pal, Murtaza M. Tambuwala. Innovative Applications of Plant Viruses in Drug Targeting and Molecular Imaging- A Review. Current Medical Imaging Formerly Current Medical Imaging Reviews. 2021; 17 (4):491-506.

Chicago/Turabian Style

Alaa A.A. Aljabali; Mazhar S. Al Zoubi; Khalid M. Al-Batayneh; Dinesh M. Pardhi; Kamal Dua; Kaushik Pal; Murtaza M. Tambuwala. 2021. "Innovative Applications of Plant Viruses in Drug Targeting and Molecular Imaging- A Review." Current Medical Imaging Formerly Current Medical Imaging Reviews 17, no. 4: 491-506.

Preprint content
Published: 18 May 2021
Reads 0
Downloads 0

Spike (S) proteins of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are critical determinants of the infectivity and antigenicity of the virus. Several mutations in the spike protein of SARS-CoV-2 have already been detected, and their effect in immune system evasion and enhanced transmission as a cause of increased morbidity and mortality are being investigated. From pathogenic and epidemiological perspectives, spike proteins are of prime interest to researchers. This study focused on the unique variants of S proteins from six continents Asia, Africa, Europe, Oceania, South America, and North America. In comparison to the other five continents, Africa (29.065%) had the highest percentage of unique S proteins. Notably, only North America had 87% (14046) of the total (16143) specific S proteins available in the NCBI database(across all continents). Based on the amino acid frequency distributions in the S protein variants from all the continents, the phylogenetic relationship implies that unique S proteins from North America were significantly different from those of the other five continents. Overtime, the unique variants originating from North America are most likely to spread to the other geographic locations through international travel or naturally by emerging mutations. Hence it is suggested that restriction of international travel should be considered, and massive vaccination as an utmost measure to combat the spread of COVID-19 pandemic. It is also further suggested that the efficacy of existing vaccines and future vaccine development must be reviewed with careful scrutiny, and if needed, further re-engineered based on requirements dictated by new emerging S protein variants.

ACS Style

Sk. Sarif Hassan; Kenneth Lundstrom; Pabitra Pal Choudhury; Giorgio Palu; Bruce D. Uhal; Ramesh Kandimalla; Murat Seyran; Amos Lal; Samendra P. Sherchan; Gajendra Kumar Azad; Alaa A. A. Aljabali; Adam M. Brufsky; Ángel Serrano-Aroca; Parise Adadi; Tarek Mohamed Abd El-Aziz; Elrashdy M. Redwan; Kazuo Takayama; Debmalya Barh; Nima Rezaei; Murtaza Tambuwala; Vladimir N. Uversky. Implications Derived from S-Protein Variants of SARS-CoV-2 from Six Continents. 2021, 1 .

AMA Style

Sk. Sarif Hassan, Kenneth Lundstrom, Pabitra Pal Choudhury, Giorgio Palu, Bruce D. Uhal, Ramesh Kandimalla, Murat Seyran, Amos Lal, Samendra P. Sherchan, Gajendra Kumar Azad, Alaa A. A. Aljabali, Adam M. Brufsky, Ángel Serrano-Aroca, Parise Adadi, Tarek Mohamed Abd El-Aziz, Elrashdy M. Redwan, Kazuo Takayama, Debmalya Barh, Nima Rezaei, Murtaza Tambuwala, Vladimir N. Uversky. Implications Derived from S-Protein Variants of SARS-CoV-2 from Six Continents. . 2021; ():1.

Chicago/Turabian Style

Sk. Sarif Hassan; Kenneth Lundstrom; Pabitra Pal Choudhury; Giorgio Palu; Bruce D. Uhal; Ramesh Kandimalla; Murat Seyran; Amos Lal; Samendra P. Sherchan; Gajendra Kumar Azad; Alaa A. A. Aljabali; Adam M. Brufsky; Ángel Serrano-Aroca; Parise Adadi; Tarek Mohamed Abd El-Aziz; Elrashdy M. Redwan; Kazuo Takayama; Debmalya Barh; Nima Rezaei; Murtaza Tambuwala; Vladimir N. Uversky. 2021. "Implications Derived from S-Protein Variants of SARS-CoV-2 from Six Continents." , no. : 1.

Journal article
Published: 18 May 2021 in International Journal of Pharmaceutics
Reads 0
Downloads 0

Our recent study showed that novel infliximab (INF) loaded polyesterurethane (INF-PU) and INF-PU-PEG particulate formulations reduced inflammation in an in-vitro epithelial inflammation model. In this study we investigated therapeutic potential of novel INF-PU and INF-PU-PEG particulate formulations to reduce inflammation in a dextran sodium sulfate (DSS) induced murine model of colitis. Severity of colitis was assessed by measurement of disease activity index (DAI) score, inflammatory markers (neutrophil infiltration, TNFα) and histological score. Treatment groups orally administered with INF-PU and INF-PU-PEG particulate formulations showed improvement in the clinical signs of colitis, similar to that observed with intraperitoneally administered INF, in both, moderate and severe DSS induced colitis model. This was related to a significant reduction in inflammatory cytokines, resulting in a significant reduction in histological score (ANOVA; p < 0.05), indicative of mucosal healing, a key goal of IBD therapy. This could be attributed to its targeted delivery to the inflamed colon and higher permeation of these particulate formulations across the inflamed colonic mucosa, as observed by the confocal images, resulting in local inhibition of TNFα at its site of production. These promising preliminary results warrant further investigation of orally administered INF and its novel particulate formulations in a wider preclinical study.

ACS Style

Ritesh M. Pabari; Murtaza M. Tambuwala; Natalia Lajczak-McGinley; Alaa Aljabali; Brian P. Kirby; Stephen Keely; Zebunissa Ramtoola. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis – A preliminary study. International Journal of Pharmaceutics 2021, 604, 120717 .

AMA Style

Ritesh M. Pabari, Murtaza M. Tambuwala, Natalia Lajczak-McGinley, Alaa Aljabali, Brian P. Kirby, Stephen Keely, Zebunissa Ramtoola. Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis – A preliminary study. International Journal of Pharmaceutics. 2021; 604 ():120717.

Chicago/Turabian Style

Ritesh M. Pabari; Murtaza M. Tambuwala; Natalia Lajczak-McGinley; Alaa Aljabali; Brian P. Kirby; Stephen Keely; Zebunissa Ramtoola. 2021. "Novel polyurethane based particulate formulations of infliximab reduce inflammation in DSS induced murine model of colitis – A preliminary study." International Journal of Pharmaceutics 604, no. : 120717.

Review article
Published: 18 May 2021 in Life Sciences
Reads 0
Downloads 0

Diabetes epidemiological quantities are demonstrating one of the most important communities' health worries. The essential diabetic difficulties are including cardiomyopathy, nephropathy, inflammation, and retinopathy. Despite developments in glucose decreasing treatments and drugs, these diabetic complications are still ineffectively reversed or prohibited. Several signaling and molecular pathways are vital targets in the new therapies of diabetes. This review assesses the newest researches about the key molecules and signaling pathways as targets of molecular pharmacology in diabetes and diseases related to it for better treatment based on molecular sciences. The disease is not cured by current pharmacological strategies for type 2 diabetes. While several drug combinations are accessible that can efficiently modulate glycemia and mitigate long-term complications, these agents do not reverse pathogenesis, and in practice, they are not established to modify the patient's specific molecular profiling. Therapeutic companies have benefited from human genetics. Genome exploration, which is agnostic to the information that exists, has revealed tens of loci that impact glycemic modulation. The physiological report has begun to examine subtypes of diseases, illustrate heterogeneity and propose biochemical therapeutic pathways.

ACS Style

Seyed Hossein Shahcheraghi; Alaa A.A. Aljabali; Mazhar S. Al Zoubi; Vijay Mishra; Nitin B. Charbe; Yusuf A. Haggag; Garima Shrivastava; Abdulmajeed G. Almutary; Abdullah M. Alnuqaydan; Debmalya Barh; Kamal Dua; Dinesh K. Chellappan; Gaurav Gupta; Marzieh Lotfi; Ángel Serrano-Aroca; Bojlul Bahar; Yogendra Kumar Mishra; Kazuo Takayama; Pritam Kumar Panda; Hamid A. Bakshi; Murtaza M. Tambuwala. Overview of key molecular and pharmacological targets for diabetes and associated diseases. Life Sciences 2021, 278, 119632 .

AMA Style

Seyed Hossein Shahcheraghi, Alaa A.A. Aljabali, Mazhar S. Al Zoubi, Vijay Mishra, Nitin B. Charbe, Yusuf A. Haggag, Garima Shrivastava, Abdulmajeed G. Almutary, Abdullah M. Alnuqaydan, Debmalya Barh, Kamal Dua, Dinesh K. Chellappan, Gaurav Gupta, Marzieh Lotfi, Ángel Serrano-Aroca, Bojlul Bahar, Yogendra Kumar Mishra, Kazuo Takayama, Pritam Kumar Panda, Hamid A. Bakshi, Murtaza M. Tambuwala. Overview of key molecular and pharmacological targets for diabetes and associated diseases. Life Sciences. 2021; 278 ():119632.

Chicago/Turabian Style

Seyed Hossein Shahcheraghi; Alaa A.A. Aljabali; Mazhar S. Al Zoubi; Vijay Mishra; Nitin B. Charbe; Yusuf A. Haggag; Garima Shrivastava; Abdulmajeed G. Almutary; Abdullah M. Alnuqaydan; Debmalya Barh; Kamal Dua; Dinesh K. Chellappan; Gaurav Gupta; Marzieh Lotfi; Ángel Serrano-Aroca; Bojlul Bahar; Yogendra Kumar Mishra; Kazuo Takayama; Pritam Kumar Panda; Hamid A. Bakshi; Murtaza M. Tambuwala. 2021. "Overview of key molecular and pharmacological targets for diabetes and associated diseases." Life Sciences 278, no. : 119632.

Journal article
Published: 17 May 2021 in Biomedicines
Reads 0
Downloads 0

It is well established that pre-existing comorbid conditions such as hypertension, diabetes, obesity, cardiovascular diseases (CVDs), chronic kidney diseases (CKDs), cancers, and chronic obstructive pulmonary disease (COPD) are associated with increased severity and fatality of COVID-19. The increased death from COVID-19 is due to the unavailability of a gold standard therapeutic and, more importantly, the lack of understanding of how the comorbid conditions and COVID-19 interact at the molecular level, so that personalized management strategies can be adopted. Here, using multi-omics data sets and bioinformatics strategy, we identified the pathway crosstalk between COVID-19 and diabetes, hypertension, CVDs, CKDs, and cancers. Further, shared pathways and hub gene-based targets for COVID-19 and its associated specific and combination of comorbid conditions are also predicted towards developing personalized management strategies. The approved drugs for most of these identified targets are also provided towards drug repurposing. Literature supports the involvement of our identified shared pathways in pathogenesis of COVID-19 and development of the specific comorbid condition of interest. Similarly, shared pathways- and hub gene-based targets are also found to have potential implementations in managing COVID-19 patients. However, the identified targets and drugs need further careful evaluation for their repurposing towards personalized treatment of COVID-19 cases having pre-existing specific comorbid conditions we have considered in this analysis. The method applied here may also be helpful in identifying common pathway components and targets in other disease-disease interactions too.

ACS Style

Debmalya Barh; Alaa Aljabali; Murtaza Tambuwala; Sandeep Tiwari; Ángel Serrano-Aroca; Khalid Alzahrani; Bruno Silva Andrade; Vasco Azevedo; Nirmal Ganguly; Kenneth Lundstrom. Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines 2021, 9, 556 .

AMA Style

Debmalya Barh, Alaa Aljabali, Murtaza Tambuwala, Sandeep Tiwari, Ángel Serrano-Aroca, Khalid Alzahrani, Bruno Silva Andrade, Vasco Azevedo, Nirmal Ganguly, Kenneth Lundstrom. Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines. 2021; 9 (5):556.

Chicago/Turabian Style

Debmalya Barh; Alaa Aljabali; Murtaza Tambuwala; Sandeep Tiwari; Ángel Serrano-Aroca; Khalid Alzahrani; Bruno Silva Andrade; Vasco Azevedo; Nirmal Ganguly; Kenneth Lundstrom. 2021. "Predicting COVID-19—Comorbidity Pathway Crosstalk-Based Targets and Drugs: Towards Personalized COVID-19 Management." Biomedicines 9, no. 5: 556.

Journal article
Published: 02 May 2021 in ASSAY and Drug Development Technologies
Reads 0
Downloads 0

Nanoemulsions (NMs) are one of the most important colloidal dispersion systems that are primarily used to improve the solubility of poorly water soluble drugs. The main objectives of this study were, first, to prepare an NM loaded with fenofibrate using a high shear homogenization technique and, second, to study the effect of variable using a central composite design. Twenty batches of fenofibrate-loaded NM formulations were prepared. The formed NMs were subjected to droplet size analysis, zeta potential, entrapment efficiency, pH, dilution, polydispersity index, transmission electron microscopy (TEM), Fourier transform infrared spectrophotometry, differential scanning calorimetry (DSC), and in vitro drug release study. Analysis of variance was used for entrapment efficiency data to study the fitness and significance of the design. The NM-7 batch formulation demonstrated maximum entrapment efficiency (81.82%) with lowest droplet size (72.28 nm), and was thus chosen as the optimized batch. TEM analysis revealed that the NM was well dispersed with droplet sizes <100 nm. Incorporation of the drug into the NM was confirmed with DSC studies. In addition, the batch NM-7 also showed the maximum in vitro drug release (87.6%) in a 0.05 M sodium lauryl sulfate solution. The release data revealed that the NM followed first-order kinetics. The outcomes of the study revealed the development of a stable oral NM containing fenofibrate using the high shear homogenization technique. This approach may aid in further enhancing the oral bioavailability of fenofibrate, which requires further in vivo studies.

ACS Style

Nisha Gulati; Dinesh Kumar Chellappan; Murtaza M. Tambuwala; Alaa A. A. Aljabali; Parteek Prasher; Sachin Kumar Singh; Krishnan Anand; Ankur Sharma; Niraj Kumar Jha; Gaurav Gupta; Kamal Dua; Harish Dureja. Oral Nanoemulsion of Fenofibrate: Formulation, Characterization, and In Vitro Drug Release Studies. ASSAY and Drug Development Technologies 2021, 19, 246 -261.

AMA Style

Nisha Gulati, Dinesh Kumar Chellappan, Murtaza M. Tambuwala, Alaa A. A. Aljabali, Parteek Prasher, Sachin Kumar Singh, Krishnan Anand, Ankur Sharma, Niraj Kumar Jha, Gaurav Gupta, Kamal Dua, Harish Dureja. Oral Nanoemulsion of Fenofibrate: Formulation, Characterization, and In Vitro Drug Release Studies. ASSAY and Drug Development Technologies. 2021; 19 (4):246-261.

Chicago/Turabian Style

Nisha Gulati; Dinesh Kumar Chellappan; Murtaza M. Tambuwala; Alaa A. A. Aljabali; Parteek Prasher; Sachin Kumar Singh; Krishnan Anand; Ankur Sharma; Niraj Kumar Jha; Gaurav Gupta; Kamal Dua; Harish Dureja. 2021. "Oral Nanoemulsion of Fenofibrate: Formulation, Characterization, and In Vitro Drug Release Studies." ASSAY and Drug Development Technologies 19, no. 4: 246-261.

Journal article
Published: 16 April 2021 in International Journal of Biological Macromolecules
Reads 0
Downloads 0

The current Coronavirus Disease 19 (COVID-19) pandemic, caused by Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) shows similar pathology to MERS and SARS-CoV, with a current estimated fatality rate of 1.4%. Open reading frame 10 (ORF10) is a unique SARS-CoV-2 accessory protein, which contains eleven cytotoxic T lymphocyte (CTL) epitopes each of nine amino acids in length. Twenty-two unique SARS-CoV-2 ORF10 variants have been identified based on missense mutations found in sequence databases. Some of these mutations are predicted to decrease the stability of ORF10 in silico physicochemical and structural comparative analyses were carried out on SARS-CoV-2 and Pangolin-CoV ORF10 proteins, which share 97.37% amino acid (aa) homology. Though there is a high degree of ORF10 protein similarity of SARS-CoV-2 and Pangolin-CoV, there are differences of these two ORF10 proteins related to their sub-structure (loop/coil region), solubility, antigenicity and shift from strand to coil at aa position 26 (tyrosine). SARS-CoV-2 ORF10, which is apparently expressed in vivo since reactive T cell clones are found in convalescent patients should be monitored for changes which could correlate with the pathogenesis of COVID-19.

ACS Style

Sk. Sarif Hassan; Diksha Attrish; Shinjini Ghosh; Pabitra Pal Choudhury; Vladimir N. Uversky; Alaa A.A. Aljabali; Kenneth Lundstrom; Bruce D. Uhal; Nima Rezaei; Murat Seyran; Damiano Pizzol; Parise Adadi; Antonio Soares; Tarek Mohamed Abd El-Aziz; Ramesh Kandimalla; Murtaza M. Tambuwala; Gajendra Kumar Azad; Samendra P. Sherchan; Wagner Baetas-Da-Cruz; Amos Lal; Giorgio Palù; Kazuo Takayama; Ángel Serrano-Aroca; Debmalya Barh; Adam M. Brufsky. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. International Journal of Biological Macromolecules 2021, 181, 801 -809.

AMA Style

Sk. Sarif Hassan, Diksha Attrish, Shinjini Ghosh, Pabitra Pal Choudhury, Vladimir N. Uversky, Alaa A.A. Aljabali, Kenneth Lundstrom, Bruce D. Uhal, Nima Rezaei, Murat Seyran, Damiano Pizzol, Parise Adadi, Antonio Soares, Tarek Mohamed Abd El-Aziz, Ramesh Kandimalla, Murtaza M. Tambuwala, Gajendra Kumar Azad, Samendra P. Sherchan, Wagner Baetas-Da-Cruz, Amos Lal, Giorgio Palù, Kazuo Takayama, Ángel Serrano-Aroca, Debmalya Barh, Adam M. Brufsky. Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2. International Journal of Biological Macromolecules. 2021; 181 ():801-809.

Chicago/Turabian Style

Sk. Sarif Hassan; Diksha Attrish; Shinjini Ghosh; Pabitra Pal Choudhury; Vladimir N. Uversky; Alaa A.A. Aljabali; Kenneth Lundstrom; Bruce D. Uhal; Nima Rezaei; Murat Seyran; Damiano Pizzol; Parise Adadi; Antonio Soares; Tarek Mohamed Abd El-Aziz; Ramesh Kandimalla; Murtaza M. Tambuwala; Gajendra Kumar Azad; Samendra P. Sherchan; Wagner Baetas-Da-Cruz; Amos Lal; Giorgio Palù; Kazuo Takayama; Ángel Serrano-Aroca; Debmalya Barh; Adam M. Brufsky. 2021. "Notable sequence homology of the ORF10 protein introspects the architecture of SARS-CoV-2." International Journal of Biological Macromolecules 181, no. : 801-809.

Journal article
Published: 15 April 2021 in Computers in Biology and Medicine
Reads 0
Downloads 0

Immune evasion is one of the unique characteristics of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) attributed to its ORF8 protein. This protein modulates the adaptive host immunity through down-regulation of MHC-1 (Major Histocompatibility Complex) molecules and innate immune responses by surpassing the host's interferon-mediated antiviral response. To understand the host's immune perspective in reference to the ORF8 protein, a comprehensive study of the ORF8 protein and mutations possessed by it have been performed. Chemical and structural properties of ORF8 proteins from different hosts, such as human, bat, and pangolin, suggest that the ORF8 of SARS-CoV-2 is much closer to ORF8 of Bat RaTG13-CoV than to that of Pangolin-CoV. Eighty-seven mutations across unique variants of ORF8 in SARS-CoV-2 can be grouped into four classes based on their predicted effects (Hussain et al., 2021) [1]. Based on the geo-locations and timescale of sample collection, a possible flow of mutations was built. Furthermore, conclusive flows of amalgamation of mutations were found upon sequence similarity analyses and consideration of the amino acid conservation phylogenies. Therefore, this study seeks to highlight the uniqueness of the rapidly evolving SARS-CoV-2 through the ORF8.

ACS Style

Sk Sarif Hassan; Alaa A. A. Aljabali; Pritam Kumar Panda; Shinjini Ghosh; Diksha Attrish; Pabitra Pal Choudhury; Murat Seyran; Damiano Pizzol; Parise Adadi; Tarek Mohamed Abd El-Aziz; Antonio Soares; Ramesh Kandimalla; Kenneth Lundstrom; Amos Lal; Gajendra Kumar Azad; Vladimir N. Uversky; Samendra P. Sherchan; Wagner Baetas-Da-Cruz; Bruce D. Uhal; Nima Rezaei; Gaurav Chauhan; Debmalya Barh; Elrashdy M. Redwan; Guy W. Dayhoff; Nicolas G. Bazan; Ángel Serrano-Aroca; Amr El-Demerdash; Yogendra K. Mishra; Giorgio Palu; Kazuo Takayama; Adam M. Brufsky; Murtaza M. Tambuwala. A unique view of SARS-CoV-2 through the lens of ORF8 protein. Computers in Biology and Medicine 2021, 133, 104380 -104380.

AMA Style

Sk Sarif Hassan, Alaa A. A. Aljabali, Pritam Kumar Panda, Shinjini Ghosh, Diksha Attrish, Pabitra Pal Choudhury, Murat Seyran, Damiano Pizzol, Parise Adadi, Tarek Mohamed Abd El-Aziz, Antonio Soares, Ramesh Kandimalla, Kenneth Lundstrom, Amos Lal, Gajendra Kumar Azad, Vladimir N. Uversky, Samendra P. Sherchan, Wagner Baetas-Da-Cruz, Bruce D. Uhal, Nima Rezaei, Gaurav Chauhan, Debmalya Barh, Elrashdy M. Redwan, Guy W. Dayhoff, Nicolas G. Bazan, Ángel Serrano-Aroca, Amr El-Demerdash, Yogendra K. Mishra, Giorgio Palu, Kazuo Takayama, Adam M. Brufsky, Murtaza M. Tambuwala. A unique view of SARS-CoV-2 through the lens of ORF8 protein. Computers in Biology and Medicine. 2021; 133 ():104380-104380.

Chicago/Turabian Style

Sk Sarif Hassan; Alaa A. A. Aljabali; Pritam Kumar Panda; Shinjini Ghosh; Diksha Attrish; Pabitra Pal Choudhury; Murat Seyran; Damiano Pizzol; Parise Adadi; Tarek Mohamed Abd El-Aziz; Antonio Soares; Ramesh Kandimalla; Kenneth Lundstrom; Amos Lal; Gajendra Kumar Azad; Vladimir N. Uversky; Samendra P. Sherchan; Wagner Baetas-Da-Cruz; Bruce D. Uhal; Nima Rezaei; Gaurav Chauhan; Debmalya Barh; Elrashdy M. Redwan; Guy W. Dayhoff; Nicolas G. Bazan; Ángel Serrano-Aroca; Amr El-Demerdash; Yogendra K. Mishra; Giorgio Palu; Kazuo Takayama; Adam M. Brufsky; Murtaza M. Tambuwala. 2021. "A unique view of SARS-CoV-2 through the lens of ORF8 protein." Computers in Biology and Medicine 133, no. : 104380-104380.